CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lymphomas.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to to facilitate the optimal care of patients with Hodgkin and non-Hodgkin lymphomas.
  
  LEARNING OBJECTIVES

  • Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory (R/R) follicular lymphoma (FL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), and use this information to enhance decision-making for patients.
  • Appraise the rationale for and available data documenting the utility of lenalidomide in combination with rituximab for newly diagnosed and R/R FL, and use this information to counsel patients regarding what role, if any, this regimen should play in their care.
  • Recognize how prior therapeutic exposure and other patient and disease characteristics, including EZH2 mutation status, affect the selection and sequencing of available systemic treatments for R/R FL.
  • Appraise the similarities and differences among commercially available Bruton tyrosine kinase inhibitors, and counsel patients regarding the selection and sequencing of these agents in the management of R/R MCL.
  • Recall existing and emerging efficacy and safety data from clinical trials of approved and investigational CAR (chimeric antigen receptor) T-cell therapies directed at CD19 for R/R B-cell lymphomas, and identify patients who may be candidates for this approach.
  • Understand the FDA-approved indications for tafasitamab/lenalidomide and lisocabtagene maraleucel for patients with R/R DLBCL, and consider how these agents can be appropriately and safely incorporated into clinical practice.
  • Evaluate updated clinical trial data with brentuximab vedotin in combination with AVD (doxorubicin/vinblastine/dacarbazine) to discern how this regimen can be optimally incorporated into front-line management of advanced classical HL.
  • Educate patients about the side effects associated with FDA-approved therapies commonly used in the management of various forms of lymphoma, and provide strategies to prevent or ameliorate these toxicities.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: This educational activity for 2 contact hours is provided by RTP during the period of May 2021 through May 2022.
  
  This activity is awarded 2 ANCC pharmacotherapeutic contact hours.
  
  Video Program: This educational activity for 1.5 contact hours is provided by RTP during the period of May 2021 through May 2022.
  
  This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSLymphomas2021/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSLymphomas2021/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/ONSLymphomas2021/Video.
  
  Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSLymphomas2021/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONSLymphomas2021.
  
  CONTENT VALIDATION AND DISCLOSURES
  RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Stephen M Ansell, MD, PhD
  Professor of Medicine
  Chair, Lymphoma Group
  Mayo Clinic
  Rochester, Minnesota
  
  Contracted Research (to Institution): ADC Therapeutics SA, Affimed, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Oncology, Trillium Therapeutics Inc.
  
  Carla Casulo, MD
  Associate Professor of Medicine
  Division of Hematology/Oncology
  Director, Hematology/Oncology Fellowship Program
  University of Rochester
  Wilmot Cancer Institute
  New York, New York
  
  No relevant conflicts of interest to disclose.
  
  John P Leonard, MD
  Richard T Silver Distinguished Professor of Hematology and Medical Oncology
  Senior Associate Dean for Innovation and Initiatives
  Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
  Weill Cornell Medicine
  New York, New York
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Miltenyi Biotec, Regeneron Pharmaceuticals Inc, Sutro Biopharma; Contracted Research: Epizyme Inc, Genentech Foundation, Janssen Biotech Inc.
  
  Oncology Nurse Practitioners
  
  Jacklyn Gideon, MSN, AGPCNP-BC
  Advanced Practice Provider
  Lead Apheresis APP
  Hematopoietic Cellular Therapy Program
  Section of Hematology/Oncology
  The University of Chicago Medicine and Biological Sciences
  Chicago, Illinois
  
  No relevant conflicts of interest to disclose.
  
  Robin Klebig, APRN, CNP, AOCNP
  Nurse Practitioner
  Assistant Professor of Medicine
  Division of Hematology
  Mayo Clinic
  Rochester, Minnesota
  
  No relevant conflicts of interest to disclose.
  
  Mollie Moran, APRN-CNP, AOCNP
  The James Cancer Hospital and Solove Research Institute
  The Ohio State University
  Columbus, Ohio
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
  
  RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Bristol-Myers Squibb Company, Epizyme Inc, Incyte Corporation, Novartis and Seagen Inc.
  
  Release date: May 2021
  Expiration date: May 2022
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.